A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody
S Gairola, M Gautam, S Waghmare - Human Vaccines & …, 2020 - Taylor & Francis
Global efforts on the replacement of the in vivo rabies vaccine potency test (NIH method)
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody
S Gairola, M Gautam… - Human vaccines & …, 2020 - pubmed.ncbi.nlm.nih.gov
Global efforts on the replacement of the in vivo rabies vaccine potency test (NIH method)
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.
S Gairola, M Gautam, S Waghmare - Human Vaccines & …, 2020 - europepmc.org
Global efforts on the replacement of the in vivo rabies vaccine potency test (NIH method)
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
[HTML][HTML] A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody
S Gairola, M Gautam, S Waghmare - Human Vaccines & …, 2020 - ncbi.nlm.nih.gov
Global efforts on the replacement of the in vivo rabies vaccine potency test (NIH method)
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …